Medicine
Briumvi 150 mg/6 mL injection
Briumvi 150 mg/6 mL injection is a prescription medicine containing Ublituximab for intravenous use, marketed by TG Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store BRIUMVI vials refrigerated at 2°C to 8°C (36°F to 46°F) in the outer…
Key facts
- Active ingredient (INN)
- Ublituximab
- Brand
- Briumvi
- Strength
- 150 mg/6 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 6 mL
- Marketing authorisation holder
- TG Therapeutics
- Manufacturer
- TG Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store BRIUMVI vials refrigerated at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04 Immunosuppressants
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 December 2022
- Identifiers
- RxCUI 2626353, 2626359DailyMed set ID 3a77cd8c-811b-407c-9140-d0c5c26435c2NDC 73150-150Application BLA761238
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 6 mL in 1 vial, single-dose | 73150-150-06 | TG Therapeutics | 28 December 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ublituximab is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Ublituximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about UblituximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BRIUMVI prescribing information (TG Therapeutics) · U.S. National Library of Medicine, DailyMed
- Briumvi: European public assessment report (EPAR) · European Medicines Agency
Need Briumvi 150 mg/6 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.